Predictors of Intracranial Hemorrhage Volume Expansion in Patients Receiving Factor Xa Inhibitors in ANNEXA‐4: Time and Severity Matter Most

Predictors of Intracranial Hemorrhage Volume Expansion in Patients Receiving Factor Xa Inhibitors in ANNEXA‐4: Time and Severity Matter Most

Background Andexanet alfa, a specific reversal agent for factor Xa inhibitors, resulted in effective hemostasis in 79% of patients with intracranial bleeding in the ANNEXA‐4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors) trial (NCT02329327). However, little...

Full description

Bibliographic Details
Main Authors: Mauricio Concha, Lizhen Xu, MacKenzie Horn, Tomoyuki Ohara, Juliet Nakamya, Jan Beyer‐Westendorf, Ashkan Shoamanesh, Alexander Cohen, Per Ladenvall, Stuart J. Connolly, Andrew M. Demchuk
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:Stroke: Vascular and Interventional Neurology
Subjects:
andexanet alfa
anti‐factor Xa activity
direct factor Xa inhibitor reversal
hematoma expansion
intracranial hemorrhage
Online Access:https://www.ahajournals.org/doi/10.1161/SVIN.123.000997

Internet

https://www.ahajournals.org/doi/10.1161/SVIN.123.000997

Similar Items